Passa al contenuto
Merck
Tutte le immagini(3)

Documenti

C0737

Sigma-Aldrich

Cilostazol

≥98% (HPLC), powder

Sinonimo/i:

6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-2(1H)-quinolinone, OPC 13013, OPC 21, Pletaal

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali


About This Item

Formula empirica (notazione di Hill):
C20H27N5O2
Numero CAS:
Peso molecolare:
369.46
Numero MDL:
Codice UNSPSC:
41106305
ID PubChem:
NACRES:
NA.77

Saggio

≥98% (HPLC)

Forma fisica

powder

Colore

off-white

Solubilità

DMSO: 10 mg/mL, clear

Ideatore

Otsuka Pharma

Stringa SMILE

O=C1CCc2cc(OCCCCc3nnnn3C4CCCCC4)ccc2N1

InChI

1S/C20H27N5O2/c26-20-12-9-15-14-17(10-11-18(15)21-20)27-13-5-4-8-19-22-23-24-25(19)16-6-2-1-3-7-16/h10-11,14,16H,1-9,12-13H2,(H,21,26)
RRGUKTPIGVIEKM-UHFFFAOYSA-N

Informazioni sul gene

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Categorie correlate

Descrizione generale

Cilostazol prevents platelet aggregation and has vasodilatory properties. It is used to treat chronic arterial disease and intermittent claudication. Cilostazol has antiproliferative effects and improves the properties of prostacyclin. It regulates cell proliferation, stimulates cyclic adenosine monophosphate (cAMP) level and induces cyclic AMP-dependent protein kinase.

Applicazioni

Cilostazol has been used:
  • to reduce Madin–Darby cell line (MDCK) proliferation through c-Myc down-regulation
  • in the in vitro assessment of toxin delivery in T84 intestinal epithelial cells
  • to induce adenosine triphosphate (ATP) release in white adipocytes

Azioni biochim/fisiol

Phosphodiesterase III (PDE3) inhibitor

Caratteristiche e vantaggi

This compound is a featured product for Cyclic Nucleotide research. Click here to discover more featured Cyclic Nucleotide products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound was developed by Otsuka Pharma. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Pittogrammi

Health hazard

Avvertenze

Warning

Indicazioni di pericolo

Classi di pericolo

Repr. 2

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Dispositivi di protezione individuale

Eyeshields, Gloves, type N95 (US)


Certificati d'analisi (COA)

Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 5

1 of 5

Sildenafil Citrate Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1807

Sildenafil Citrate

(±)-Thalidomide ≥98%, powder

Sigma-Aldrich

T144

(±)-Thalidomide

Sildenafil citrate United States Pharmacopeia (USP) Reference Standard

USP

1612561

Sildenafil citrate

Rifampicin suitable for plant cell culture, BioReagent, ≥95% (HPLC), powder or crystals

Sigma-Aldrich

R7382

Rifampicin

Forskolina from Coleus forskohlii, ≥98% (HPLC), powder

Sigma-Aldrich

F6886

Forskolina

Kuang-Yi Tseng et al.
Medicina (Kaunas, Lithuania), 59(3) (2023-03-30)
Background and Objective: Our previous study demonstrated that consistent treatment of oral cilostazol was effective in reducing levels of painful peripheral neuropathy in streptozotocin-induced type I diabetic rats. As diabetic neuropathy is characterized by hyperglycemia-induced nerve damage in the periphery
Pannexin-1 mediated ATP release in adipocytes is sensitive to glucose and insulin and modulates lipolysis and macrophage migration
Tozzi M, et al.
bioRxiv, 380469-380469 (2018)
Sayuri N Friedland et al.
The American journal of cardiology, 109(10), 1397-1404 (2012-03-03)
Cilostazol is a generic drug with antiplatelet and antiproliferative effects. It is unclear whether adding cilostazol to standard dual antiplatelet therapy (aspirin and clopidogrel) after percutaneous coronary intervention reduces restenosis and improves the outcomes. We, therefore, conducted a systematic review
James J Dinicolantonio et al.
The American journal of cardiology, 112(8), 1230-1234 (2013-07-06)
Aspirin is the most widely prescribed antiplatelet agent for the secondary prevention of stroke. Cilostazol, an antiplatelet and vasodilating agent, has shown promise for the secondary prevention of stroke. A systematic review and meta-analysis of randomized controlled trials using Ovid
Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease
Money SR, et al.
Journal of Vascular Surgery, 27(2), 267-275 (1998)

Articoli

Cyclic nucleotides like cAMP modulate cell function via PKA activation and ion channels.

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.